Compared to women in the study who were given placebo, women on the statin therapy nearly cut in half their risk for cardiovascular disease, a risk reduction similar to those found among men in the study. The findings appear in the February 22, 2009 on line edition of the journal Circulation.
The JUPITER findings were also compared to a meta-analysis of five peer- reviewed, randomized, placebo-controlled statin trials. Put in context with this material, the women on statin therapy from the meta-analysis had a one third reduced risk of CVD compared to those taking a placebo.
For this research, 6801 female participants in the JUPITER study, who did not have cardiovascular disease, were greater than age 60 with acceptable levels of LDL cholesterol but elevated hsCRP, were randomized to receive rosuvastatin or placebo. Among the group receiving rosuvastatin, the researchers found cardiovascular events such as heart attack, stroke, unstable angina, and revascularization were reduced by 46 percent compared to women in the study who received the placebo. Previous findings from JUPITER showed men on resovastatin therapy reduced their CVD risks by 42 percent compared to men in the study taking the placebo
“Our findings show for the first time that apparently healthy women with acceptable cholesterol levels but higher hsCRP would benefit from statin therapy,” said Samia Mora MD, lead author of the study and a researcher in the BWH Center for Cardiovascular Disease Prevention. “We now have a new tool to better protect women from the risks of cardiovascular disease, since more women die each year from cardiovascular disease than all cancers combined.”
The research was funded by AstraZeneca.